Severe interstitial pneumonitis associated with infliximab therapy.
Chatterjee
S
S
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004417:Dyspnea / Q000209:etiology; D005260:Female; D006801:Humans; D000069285:Infliximab; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000473:pathology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab